BRAIN Biotech spinout Akribion Therapeutics announces investors in its seed financing round for the in vivo proof of concept of its G-Dase® E technology

According to the Akribion Therapeutics press release, the round was led by CARMA FUND and RV Invest, with participation from MP Beteiligungs GmbH, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. The Company intends to use the seed capital to achieve in vivo proof of concept for its proprietary G-dase® E technology. The enzyme-based technology is the basis for novel therapeutics that Akribion expects to develop for precision disease cell depletion therapies in cancer treatment.

The biotech start-up, which will initially focus its research on HPV-induced oropharyngeal head and neck cancer (OPSCC), is now exploring applications in other oncology indications, as well as autoimmune diseases, fibrosis, infectious diseases and more.

According to Akribion, the flexibility and broad potential of the G-dase® E technology represents a promising platform for different therapeutic areas, as the technology can be quickly adapted to different cell types. As a result, the Company believes that new therapies can be developed more flexible and faster than with conventional methods.

G-dase® E comes from BRAIN Biotech's BioIncubator

G-dase® E, a CAS like but novel nuclease,was originally developed at BRAIN Biotech's research campus in Zwingenberg, Germany. In October 2024, BRAIN Biotech signed an exclusive technology license agreement with Akribion Therapeutics GmbH for the use of the nuclease in the pharmaceutical sector.

G-dase® E is part of BRAIN Biotech's proprietary CRISPR-Cas nuclease portfolio and was developed as part of the company's BioIncubator pipeline for highly innovative projects. BRAIN Biotech intends to commercialize and monetize further high-value projects from its BioIncubator pipeline in the coming years.

For further information about Akribion Therapeutics, please visit the Company´s website:
akribion-therapeutics.com